Why BDX Matters Now
Becton, Dickinson and Company is trading near its historical undervaluation band. Current yield 2.4% vs historical max 2.6% (92% of maximum). 14 consecutive years without a dividend cut. Reasonable payout ratio of 73%.
Weiss Valuation: Where Does BDX Stand Today?
At 2.40%, BDX's current yield is near the top of its 10-year historical range (1.37%–2.61%), reaching 92% of its historical maximum. This places the stock firmly in historically undervalued territory by the Weiss method — the kind of entry point that has preceded strong long-term returns for income investors.
The undervalued price threshold — the level at which BDX historically becomes an attractive buy — currently sits at $180.80. The overvalued threshold, above which the stock is historically expensive, is $278.10. The current price of $155.92 places the stock below the undervalued band — a historically rare buying opportunity.
Dividend Quality Assessment
Becton, Dickinson and Company scores 70/100 on DividendVisual's quality scale — a Good rating, indicating a well-covered, growing dividend with manageable risk. Key metrics: a 73% payout ratio, the dividend consumes 26% of free cash flow, growing at 6.0% annually over the past 5 years.
Becton, Dickinson and Company has raised its dividend for 54 consecutive years — qualifying it as a Dividend King, the most elite category of income stocks.
The current payout ratio is 73% — a moderate level. The dividend is well-covered but investors should monitor any trend toward higher payout.
Peer Context: Is BDX the Best Setup?
BDX is not the only candidate in Healthcare. AMGN offers a higher current yield, while SYK screens higher on quality. That makes peer comparison important before treating BDX's Weiss signal as the best available setup.
10-Year Yield History
Over the past decade, Becton, Dickinson and Company's dividend yield has ranged from a low of 1.37% (when the stock was most expensive relative to its dividend) to a high of 2.61% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 1.70%.
Investors who consistently bought BDX near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What BDX Could Generate
A $10,000 investment at the current price and yield would generate approximately $240 in year-one income. With dividends reinvested and a 6.0% annual growth rate maintained, that same investment would produce roughly $595 per year in income by year 10 — a yield on cost of 6.0%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Becton, Dickinson and Company's dividend appears well-supported by current earnings and cash flow. No material red flags are flagged by the quality model, though macro risks (rising rates, sector disruption) always apply.
For healthcare dividend stocks, patent cycles, reimbursement pressure, product pipelines, and litigation can matter as much as current payout ratios. A safe-looking dividend still needs durable earnings power behind it.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Becton, Dickinson and Company's position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
What to Watch Next
- Yield moving toward 2.61% would strengthen the undervaluation signal; yield falling toward 1.70% would indicate mean reversion.
- Payout ratio staying below 73% would support dividend flexibility.
- Free-cash-flow payout near 26% should be monitored for deterioration.
- Dividend growth above 6.0% would confirm the income-compounding case; a slowdown would reduce the appeal.
- Any break in the 54-year dividend growth streak would materially change the thesis.
Bottom Line
Becton, Dickinson and Company currently offers a historically attractive entry point for income investors. The combination of an above-median yield, a quality score of 70/100, and 54 years of dividend growth makes a compelling case for consideration at current levels. As always, position sizing and portfolio context matter — but the Weiss signal here is meaningful.